Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases.
The treatment of renal limited systemic vasculitis usually involves a combination of cytotoxic drugs and steroids. As shown by randomised prospective controlled trial, plasmapheresis may be of additional benefit for the management of patients with renal involvement severe enough to require dialysis...
Principais autores: | Elliott, J, Lockwood, C, Hale, G, Waldmann, H |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
1998
|
Registros relacionados
-
Monoclonal-antibody therapy in systemic vasculitis.
por: Mathieson, P, et al.
Publicado em: (1990) -
MONOCLONAL-ANTIBODY THERAPY IN SYSTEMIC VASCULITIS
por: Mathieson, P, et al.
Publicado em: (1990) -
HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS
por: Lockwood, C, et al.
Publicado em: (1993) -
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
por: Lockwood, C, et al.
Publicado em: (1993) -
MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY
por: Isaacs, J, et al.
Publicado em: (1993)